New Delhi, Nov. 2 -- New Delhi : Akums Drugs & Pharmaceuticals Ltd., India's largest Contract Development and Manufacturing Organisation (CDMO), announced its consolidated financial results for the quarter ended September 30, 2026. The Company delivered strong growth in revenue, operating profitability and profit after tax, supported by continued momentum in its CDMO business, healthy customer demand and improved operating performance.
For Q2 FY27, Akums reported revenue of Rs.1,342 crore, registering a year-on-year growth of 31.9% compared to Rs.1,018 crore in Q2 FY26. EBITDA increased by 106% year-on-year to
Rs.195 crore, compared to Rs.94 crore in the corresponding quarter last year. EBITDA margin improved to 14.5% from 9.3% in Q2 FY26...